op-3136
·Code: OP-3136
op-3136: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | Phase 1 |
FDA Decisions
FDA_MeetingFDA cleared the IND for OP-3136, a selective KAT6 inhibitor; company expects to initiate a Phase 1 clinical trial in early 2025.(OLMA)
Frequently asked questions
Who is developing op-3136?
op-3136 is being developed by Olema Pharmaceuticals, Inc..
What is op-3136's latest FDA decision?
The most recent tracked FDA decision for op-3136 is FDA_Meeting for FDA cleared the IND for OP-3136, a selective KAT6 inhibitor; company expects to initiate a Phase 1 clinical trial in early 2025., dated December 9, 2024.
Get deeper analysis on op-3136
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis